Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)- or STAT3-targeting moiety.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered dual antagonists of endothelin ETA receptor (EDNRA; ETRA) and angiotensin AT1 receptor (AGTR1; AT1). They are reported to be useful for the treatment of chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis and hypertension.
Nanjing Anji Biotechnology Co. Ltd. has discovered 2-oxoglutarate dehydrogenase, mitochondrial (OGDH; OGDC-E1) inhibitors. They are reported to be useful for the treatment of schizophrenia, liver fibrosis, liver cancer, diabetic nephropathy, heart failure, Alzheimer’s, Parkinson’s and Huntington’s disease, among others.
Aurigene Oncology Ltd. has identified compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Ewha Womans University has reported Bruton tyrosine kinase (BTK) inhibitors described as potentially useful for the treatment of autoimmune disease and cancer.
Yuhan Corp. has disclosed triggering receptor expressed on myeloid cells 2 (TREM2) agonists described as potentially useful for the treatment of neurological disorders.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of arthritis and psoriasis.
RSS